Invirsa develops a molecule that promotes ocular DNA repair and the innate immune response to infection and injury.
Invirsa has raised $7.7M in total funding. The most recent round was Series B. The last funding was announced in June 2023.
Invirsa's investors include Jumpstart Ventures, Rev1 Ventures, CincyTech, JobsOhio.
Invirsa is headquartered in Columbus, United States.
Invirsa develops a molecule that promotes ocular DNA repair and the innate immune response to infection and injury.
Invirsa is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Invirsa — Funding & Investors." VCBacked, June 14, 2023, https://www.vcbacked.co/company/invirsa. Accessed August 14, 2026.
VCBacked. (2023). Invirsa — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/invirsa
{{cite web |title=Invirsa — Funding & Investors |url=https://www.vcbacked.co/company/invirsa |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated